You can access the MAYZENT materials below, which have been designed to support you and your SPMS patients. These materials will provide you with more in-depth information about MAYZENT, and support you in the day-to-day management of patients receiving MAYZENT.
A letter for GPs of patients who have been prescribed MAYZENT, detailing information relevant to primary care.
CYP2C9 DRUG-DRUG INTERACTIONS LEAFLET
A leaflet detailing recommendations regarding interactions with the cytochrome P450 pathway in patients who have been prescribed MAYZENT.
THE EXPAND STUDY ANIMATION
A video highlighting key MAYZENT efficacy and safety data for the treatment of SPMS with active disease, as demonstrated in the pivotal phase III study, EXPAND.
MAYZENT SWITCH TOOL
The MAYZENT switch tool provides guidance on how to switch patients to MAYZENT from other treatments.
MAYZENT CLINICAL PROTOCOL
The purpose of this document is to provide you with a template and useful information to support with the development of your local clinical protocol for MAYZENT treatment.
MayzentConnect HCP LEAFLET
A leaflet with information on MayzentConnect* offerings and setting up process.
*MayzentConnect is offered as a package deal, developed and funded by Novartis Pharmaceuticals UK Ltd. MayzentConnect is for NHS patients who are receiving MAYZENT or for whom the prescribing decision has been made. A service level agreement is required for each NHS organisation participating.
Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1
SPMS, secondary progressive multiple sclerosis.
- MAYZENT (siponimod) Summary of Product Characteristics.